Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Familial hypercholesterolaemia.

A David Marais1

  • 1Lipidology Division of Internal Medicine, University of Cape Town Health Science Faculty, Observatory 7925, Republic of South Africa. dmarais@capeheart.uct.ac.za

The Clinical Biochemist. Reviews
|June 3, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.

European heart journal·2025
Same author

Homozygous Familial Hypercholesterolemia Treatment: New Developments.

Current atherosclerosis reports·2025
Same author

Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial.

Journal of clinical lipidology·2023
Same author

The association between a genetic variant in the <i>SULF2</i> gene, metabolic parameters and vascular disease in patients at high cardiovascular risk.

Cardiovascular endocrinology & metabolism·2023
Same author

Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia.

Clinica chimica acta; international journal of clinical chemistry·2022
Same author

Clinical heterogeneity in monogenic chylomicronaemia.

BMJ case reports·2022
Same journal

The Emerging Role of Copeptin.

The Clinical biochemist. Reviews·2022
Same journal

Proceedings of the Australasian Association of Clinical Biochemistry and Laboratory Medicine's 2021 Virtual Scientific Conference.

The Clinical biochemist. Reviews·2022
Same journal

Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting.

The Clinical biochemist. Reviews·2021
Same journal

The Role of PINP in Diagnosis and Management of Metabolic Bone Disease.

The Clinical biochemist. Reviews·2021
Same journal

Proceedings of the Australasian Association of Clinical Biochemistry and Laboratory Medicine's 2020 Virtual Scientific Conference.

The Clinical biochemist. Reviews·2020
Same journal

Vitamin D Metabolism and Guidelines for Vitamin D Supplementation.

The Clinical biochemist. Reviews·2020
See all related articles

Familial hypercholesterolaemia (FH) is a genetic disorder causing high cholesterol and early heart disease due to defects in genes regulating LDL cholesterol clearance. Genetic diagnosis improves disease detection and understanding of FH phenotypes.

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cardiovascular Disease

Background:

  • Familial hypercholesterolaemia (FH) is an inherited condition characterized by extremely high cholesterol levels, tendon xanthomas, and premature cardiovascular disease.
  • It results from mutations in genes involved in low-density lipoprotein (LDL) metabolism, including the LDL receptor, apolipoprotein B (apoB), PCSK9, and the ARH adaptor protein.
  • These genetic defects lead to impaired clearance of LDL cholesterol from the circulation.

Purpose of the Study:

  • To review normal cholesterol and lipoprotein metabolism.
  • To describe the genetic disorders causing FH, their metabolic disturbances, and clinical manifestations.
  • To classify FH into distinct phenotypes based on metabolic derangement severity and discuss genetic diagnosis and population migration.

Related Experiment Videos

Main Methods:

  • Review of literature on sterol and lipoprotein metabolism.
  • Description of genetic defects in FH, including LDL receptor, apoB, PCSK9, and ARH pathways.
  • Classification of FH into heterozygous and homozygous phenotypes based on genetic cause and metabolic severity.

Main Results:

  • FH is caused by defects in at least four genes, with varying gene-dose effects impacting LDL clearance.
  • Heterozygous FH involves defects in LDL receptor, apoB100, or NPC1L1, while homozygous FH involves LDL receptor or ARH mutations.
  • Genetic diagnosis of FH enhances disease definition, detection, and provides insights into population migration patterns.

Conclusions:

  • FH presents distinct phenotypes (heterozygous and homozygous) with significant atherosclerosis risk, particularly in homozygous individuals.
  • Understanding the genetic basis and metabolic derangements is crucial for accurate diagnosis and management.
  • Genetic diagnosis aids in identifying FH, understanding its population dynamics, and guiding treatment strategies.